Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Radiotherapy for metastatic prostate cancer-Authors' reply.

Parker CC, James ND, Brawley CD, Clarke NW, Parmar MKB.

Lancet. 2019 Sep 7;394(10201):830. doi: 10.1016/S0140-6736(19)31829-X. No abstract available.

PMID:
31498099
2.

Salvage radiotherapy for patients with rising PSA - Authors' reply.

Carrie C, Dussart S.

Lancet Oncol. 2016 Aug;17(8):e315. doi: 10.1016/S1470-2045(16)30296-0. No abstract available.

PMID:
27511152
4.

Postoperative radiotherapy for high-risk prostate cancer - Authors' reply.

Bolla M, Collette L.

Lancet. 2013 Mar 30;381(9872):1093. doi: 10.1016/S0140-6736(13)60752-7. No abstract available.

PMID:
23540845
5.

Adjuvant radiotherapy following radical prostatectomy for prostate cancer.

Daly T, Hickey BE, Lehman M, Francis DP, See AM.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD007234. doi: 10.1002/14651858.CD007234.pub2. Review.

PMID:
22161411
6.

Assessing robot-assisted laparoscopic prostatectomy - Authors' reply.

Yaxley JW, Coughlin GD, Chambers SK, Dunglison N, Gardiner RA.

Lancet. 2017 Feb 25;389(10071):800-801. doi: 10.1016/S0140-6736(17)30508-1. No abstract available.

PMID:
28248170
7.

Radiotherapy for metastatic prostate cancer.

Aparicio A, Thall P, Logothetis C.

Lancet. 2019 Sep 7;394(10201):829-830. doi: 10.1016/S0140-6736(19)31783-0. No abstract available.

PMID:
31498098
8.

Radiotherapy for metastatic prostate cancer.

Gouda MA.

Lancet. 2019 Sep 7;394(10201):829. doi: 10.1016/S0140-6736(19)31782-9. No abstract available.

PMID:
31498097
9.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
10.

Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.

Dall'Era MA, Lo MJ, Chen J, Cress R, Hamilton AS.

Cancer. 2018 May 1;124(9):1921-1928. doi: 10.1002/cncr.31285. Epub 2018 Mar 2.

12.

In reply to Dr. King (Adjuvant radiotherapy after prostatectomy: does waiting for a detectable prostate-specific antigen level make sense?).

Ohri N, Dicker AP, Showalter TN.

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1279. doi: 10.1016/j.ijrobp.2011.02.032. No abstract available.

PMID:
21683890
13.

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.

Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED.

JAMA. 2006 Nov 15;296(19):2329-35.

PMID:
17105795
14.

Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy.

Zumsteg ZS, Daskivich TJ, Sandler HM.

J Clin Oncol. 2016 Nov 10;34(32):3829-3833. doi: 10.1200/JCO.2016.69.2509.

PMID:
27573664
17.

Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging.

Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ.

J Urol. 2018 Mar;199(3):726-733. doi: 10.1016/j.juro.2017.09.033. Epub 2017 Sep 12.

PMID:
28916273
18.

Reply from Authors re: Matthew T. Gettman. Assessing Work Disability After Radical Prostatectomy. Eur Urol 2016;70:72-3: The Challenge of Assessing Work Disability.

Plym A, Voss M, Stattin P, Lambe M.

Eur Urol. 2016 Jul;70(1):73-74. doi: 10.1016/j.eururo.2016.01.040. Epub 2016 Feb 9. No abstract available.

PMID:
26873837
19.

Prospective study of urinary tract infections and urinary antibodies after radical prostatectomy and cystoprostatectomy.

Iwakiri J, Freiha FS, Shortliffe LM.

Urol Clin North Am. 2002 Feb;29(1):251-8, xii.

PMID:
12109353

Supplemental Content

Support Center